Bruker launches NMR-based long COVID test

Create PDF

August 2022—Bruker Corp. has launched PhenoRisk PACS RuO, a research use only nuclear magnetic resonance test for molecular phenomics research on blood samples of patients with post-acute COVID syndrome (PACS), or long COVID. The test uses a multiplexed combination of biomarkers and is for research on early-stage risk factors on longitudinal recovery monitoring and on potential secondary organ damage in cardiovascular disease, type 2 diabetes, kidney dysfunction, and inflammation. It runs on the Avance IVDr NMR spectroscopy system, which produces results in 20 minutes.